Marcos Arturo MartÃ-nez-Banaclocha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8444845/publications.pdf

Version: 2024-02-01



Marcos Arturo

#	Article	IF	CITATIONS
1	Interfering with the Reactive Cysteine Proteome in COVID-19. Current Medicinal Chemistry, 2022, 29, 1657-1663.	1.2	2
2	N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases. Antioxidants, 2022, 11, 416.	2.2	10
3	Proteomic Complexity in Parkinson's Disease: A Redox Signaling Perspective of the Pathophysiology and Progression. Neuroscience, 2021, 453, 287-300.	1.1	6
4	Potential Role of Nâ€Acetylâ€Cysteine in the Cysteine Proteome in Parkinson's Disease?. Clinical Pharmacology and Therapeutics, 2020, 107, 1055-1055.	2.3	8
5	Astroglial Isopotentiality and Calcium-Associated Biomagnetic Field Effects on Cortical Neuronal Coupling. Cells, 2020, 9, 439.	1.8	16
6	N-acetyl-cysteine in Schizophrenia: Potential Role on the Sensitive Cysteine Proteome. Current Medicinal Chemistry, 2020, 27, 6424-6439.	1.2	5
7	Ephaptic Coupling of Cortical Neurons: Possible Contribution of Astroglial Magnetic Fields?. Neuroscience, 2018, 370, 37-45.	1.1	17
8	N-acetylcysteine in Psychiatric Disorders: Possible Role of Cysteinet Deregulation. International Neuropsychiatric Disease Journal, 2018, 12, 1-6.	0.1	2
9	Cysteinet Dysregulation in Muscular Dystrophies: A Pathogenic Network Susceptible to Therapy. Current Medicinal Chemistry, 2017, 24, 312-330.	1.2	3
10	Cysteine Network (CYSTEINET) Dysregulation in Parkinson's Disease: Role of N-acetylcysteine. Current Drug Metabolism, 2016, 17, 368-385.	0.7	7
11	Cellular Cysteine Network (CYSTEINET): Pharm-acological Intervention in Brain Aging and Neurodegenerative Diseases. , 2016, , 105-172.		4
12	N-Acetylcysteine: A Natural Antidote for Alzheimer's Disease. Alzheimers Disease & Dementia, 2016, 1, .	0.0	1
13	Ultrastructural Pathology of Anaplastic and Grade II Ependymomas reveals Distinctive Ciliary Structures – Electron Microscopy Redux. Ultrastructural Pathology, 2015, 39, 23-29.	0.4	10
14	mRNA In Situ Hybridization (HistoSonda). Diagnostic Molecular Pathology, 2012, 21, 84-92.	2.1	11
15	«El hábito no hace al monje»… pero ayuda a reconocerlo. Revista Espanola De Patologia, 2012, 45, 257-258.	0.6	0
16	N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?. Medical Hypotheses, 2012, 79, 8-12.	0.8	37
17	Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish study. Histopathology, 2011, 58, 863-869.	1.6	63
18	Molecular Diagnosis of Sentinel Lymph Nodes for Breast Cancer. Diagnostic Molecular Pathology, 2011, 20, 18-21.	2.1	18

MARCOS ARTURO

#	Article	IF	CITATIONS
19	Long-term memory in brain magnetite. Medical Hypotheses, 2010, 74, 254-257.	0.8	37
20	Spontaneous Neocortical Activity and Cognitive Functions: A Neuron-Astroglial Bio-Magnetic and Self-Organized Process. NeuroQuantology, 2010, 8, .	0.1	1
21	Neuromagnetic dialogue between neuronal minicolumns and astroglial network: A new approach for memory and cerebral computation. Brain Research Bulletin, 2007, 73, 21-27.	1.4	41
22	Fine-needle aspiration cytology of metastatic nasopharyngeal carcinoma. Diagnostic Cytopathology, 2005, 32, 233-237.	0.5	27
23	MAGNETIC STORAGE OF INFORMATION IN THE HUMAN CEREBRAL CORTEX: A HYPOTHESIS FOR MEMORY. International Journal of Neuroscience, 2005, 115, 329-337.	0.8	13
24	Laparoscopic colectomy for primary colonic lymphoma. Revista Espanola De Enfermedades Digestivas, 2005, 97, 744-9.	0.1	9
25	Architectural organisation of neuronal activity-associated magnetic fields: a hypothesis for memory. Medical Hypotheses, 2004, 63, 481-484.	0.8	6
26	Antioxidants Inhibit the Human Cortical Neuron Apoptosis Induced by Hydrogen Peroxide, Tumor Necrosis Factor Alpha, Dopamine and Beta-amyloid Peptide 1-42. Free Radical Research, 2002, 36, 1179-1184.	1.5	53
27	Are neuronal activity-associated magnetic fields the physical base for memory?. Medical Hypotheses, 2002, 59, 555-559.	0.8	10
28	Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases. Medical Hypotheses, 2001, 56, 472-477.	0.8	97
29	Increased cAMP immunostaining in cerebral vessels in Alzheimer's disease. Brain Research, 2001, 922, 148-152.	1.1	22
30	N-Acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease. Brain Research, 2000, 859, 173-175.	1.1	72
31	Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease. Brain Research, 2000, 869, 216-219.	1.1	82
32	N-Acetylcysteine delays age-associated memory impairment in mice: role in synaptic mitochondria. Brain Research, 2000, 855, 100-106.	1.1	69
33	N-Acetylcysteine elicited increase in cytochrome c oxidase activity in mice synaptic mitochondria. Brain Research, 1999, 842, 249-251.	1.1	25
34	Hypothesis: Can N-acetylcysteine be beneficial in Parkinson's disease?. Life Sciences, 1999, 64, 1253-1257.	2.0	55
35	N-Acetylcysteine protects against age-related increase in oxidized proteins in mouse synaptic mitochondria. Brain Research, 1997, 762, 256-258.	1.1	57
36	Effects of turmeric on blood and liver lipoperoxide levels of mice: Lack of toxicity. Age, 1995, 18, 171-174.	3.0	17

MARCOS ARTURO

#	Article	IF	CITATIONS
37	Glucose deprivation increases aspartic acid release from synaptosomes of aged mice. Brain Research, 1995, 673, 149-152.	1.1	6
38	Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Mechanisms of Ageing and Development, 1995, 84, 77-81.	2.2	29
39	N-Acetylcysteine protects against age-related decline of oxidative phosphorylation in liver mitochondria. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 292, 333-335.	0.8	36
40	Impairment of mitochondrial oxidative phosphorylation in the brain of aged mice. Brain Research, 1994, 644, 335-338.	1.1	82
41	Changes in plasma concentrations of vasoactive neuropeptides in patients with sepsis and septic shock. Life Sciences, 1994, 56, 75-81.	2.0	5
42	Neuropeptides and interleukin-6 in human joint inflammation. Relationship between intraarticular substance P and interleukin-6 concentrations. Neuroscience Letters, 1994, 170, 251-254.	1.0	58
43	Age-related changes in glutathione and lipid peroxide content in mouse synaptic mitochondria: Relationship to cytochrome c oxidase decline. Neuroscience Letters, 1994, 170, 121-124.	1.0	52
44	Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1993, 6, 1-9.	1.2	60
45	Alterations of anorectic cytokine levels from plasma and cerebrospinal fluid in idiopathic senile anorexia. Mechanisms of Ageing and Development, 1993, 72, 145-153.	2.2	19
46	Altered cerebrospinal fluid amino acid pattern in the anorexia of aging: Relationship with biogenic amine metabolism. Life Sciences, 1993, 53, 1643-1650.	2.0	17
47	Plasma molecular forms of gastrin, neurotensin and somatostatin in pregnancy and gestational diabetes after an oral glucose load or a mixed meal. Regulatory Peptides, 1993, 47, 73-80.	1.9	3
48	Alterations in plasma and cerebrospinal fluid levels of neuropeptides in idiopathic senile anorexia. Regulatory Peptides, 1993, 49, 109-117.	1.9	53
49	Relationship of interleukin-1 ^î ² and β2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. Journal of Neuroimmunology, 1993, 48, 235-240.	1.1	35
50	Serum levels of zinc and copper in patients with Parkinson's disease. Journal of the Neurological Sciences, 1992, 112, 30-33.	0.3	52